A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), or Post–Essential Thrombocythemia MF (Post–ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Project: Research

Project Details

Effective start/end date26/08/2125/08/26


  • phase 2 and 3 study
  • Myelofibrosis
  • treatment efficacy
  • treatment safety